Table 1.
Clinical and demographic characteristics of IBD patients in this study.
| UC | CD | |
|---|---|---|
| Samples, n | 74 | 20 |
| Sex (female/male) | 25/49 | 7/13 |
| Age median [IQR] | 49.0 [39.8–58.0] | 41.5 [36.0–60.3] |
| Disease activitya (%) | ||
| Remission stage | 78.2 | 75.0 |
| Active stage | 21.8 | 25.0 |
| Duration of disease (median years) [IQR] | 6.7 [2.3–11.6] | 10.4 [4.4–18.9] |
| Disease extentb (%) | ||
| Proctitis [E1] | 16.2 | − |
| Left-sided-colitis [E2] | 31.1 | − |
| Pancolitis [E3] | 52.7 | − |
| Disease locationb (%) | ||
| Ileum [L1] | − | 30.0 |
| Colon [L2] | − | 0.0 |
| Ileum + colon [L3] | − | 70.0 |
| Upper GI [L4] | − | 0.0 |
| Behaviourb (%) | ||
| Non-constricting, non-penetrating [B1] | − | 20.0 |
| Stricturing [B2] | − | 60.0 |
| Penetrating [B3] | − | 10.0 |
| Stricturing and penetrating [B2 + 3] | − | 10.0 |
| Medication (%) | ||
| 5-aminosalicylate | 83.0 | 88.2 |
| Azathioprine/6-mercaptopurine | 39.7 | 11.8 |
| Anti-TNFα agents | 9.4 | 41.2 |
| Vedolizumab | 1.9 | 0.0 |
| Steroid | 11.3 | 5.9 |
| Tacrolimus | 6.8 | 0.0 |
| Endoscopic activity | ||
| MES = 0/1/2/3 | 23/19/20/7 | − |
| mSES-CD = 0–2/3–6/7– | − | 10/4/6 |
IBD inflammatory bowel disease, UC ulcerative colitis, CD Crohn’s disease, IQR interquartile range, GI gastrointestinal. aAssessment of clinical disease activity by using partial Mayo score for UC (remission: 0–2 points, active: 3–9 points) and Crohn's Disease Activity Index (CDAI, remission: 0–150 points, active: > 150 points). bAssessment of disease extent, disease location, and disease behaviour by using the Montreal classification. TNF tumor necrosis factor, MES Mayo endoscopic subscore, mSES-CD modified simple endoscopic score for CD.